Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
-
2501
-
2502
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2503
-
2504
-
2505
-
2506
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2507
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2508
-
2509
-
2510
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2511
-
2512
-
2513
-
2514
-
2515
-
2516
-
2517
-
2518
-
2519
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: -
2520